GRAL vs HAE
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
GRAL · Grail$121.44 ▲ 1.94%
HAE · Haemonetics$119.93 ▼ 3.37%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- GRAL +42.7%
- HAE +70.2%
Head to head
| Metric | GRAL | HAE |
|---|---|---|
| Price | $121.44 | $119.93 |
| Change today | ▲ 1.94% | ▼ 3.37% |
| Market cap | $5.46B | $5.46B |
| Return, 3 months | +62.3% | +38.5% |
| Return, year to date | +41.9% | +49.6% |
| Return, 1 year | +52.9% | +75.4% |
| P/E (TTM) | -13.2 | 53.1 |
| P/B | 2.2 | 6.1 |
| P/E percentile vs own 5y | 1st | 81st |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +25.7% | +5.6% |
| Net profit growth (YoY) | +3.3% | -3.0% |
| Gross margin | -31.3% | 59.0% |
| Operating margin | -323.0% | 18.1% |
| Net margin | -236.9% | 7.1% |
| Return on equity | -16.1% | 11.2% |
| Analyst target vs. price | +18.3% | +9.2% |
| Analyst buy share | 86% | 88% |
| RSI (14) | 45 | 55 |
| 30-day volatility | 106.4% | 54.0% |
| Max drawdown, 1 year | -62.9% | -40.1% |
| Trend read | Leaning bearish | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- HAE is the largest of the group by market value.
- HAE has returned the most over the past year.
- GRAL carries the lowest trailing P/E.
- GRAL is growing revenue fastest.
- HAE keeps the most profit per dollar of sales.
- HAE has been the calmest stock over the last 30 days.